Oconvision Bio-B announced that the OT-802 phase III clinical trial authorization for the group's self-developed product was recently approved by the Drug Evaluation Center of the China Drug Administration. OT-802 is used to treat presbyopia. Preclinical studies have shown that it has the characteristics of rapid efficacy and high safety. The Group will commence OT-802 phase III clinical trials as soon as possible.

Zhitongcaijing · 06/10 04:25
Oconvision Bio-B announced that the OT-802 phase III clinical trial authorization for the group's self-developed product was recently approved by the Drug Evaluation Center of the China Drug Administration. OT-802 is used to treat presbyopia. Preclinical studies have shown that it has the characteristics of rapid efficacy and high safety. The Group will commence OT-802 phase III clinical trials as soon as possible.